NZ331771A - Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also included - Google Patents
Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also includedInfo
- Publication number
- NZ331771A NZ331771A NZ331771A NZ33177197A NZ331771A NZ 331771 A NZ331771 A NZ 331771A NZ 331771 A NZ331771 A NZ 331771A NZ 33177197 A NZ33177197 A NZ 33177197A NZ 331771 A NZ331771 A NZ 331771A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methods
- amino acid
- amphipathic
- inactivation
- activation
- Prior art date
Links
- 230000002101 lytic effect Effects 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title 1
- 210000004899 c-terminal region Anatomy 0.000 title 1
- 230000002779 inactivation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 6
- 229940024606 amino acid Drugs 0.000 abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 2
- YEDNBEGNKOANMB-REOHCLBHSA-N (2r)-2-amino-3-sulfanylpropanamide Chemical compound SC[C@H](N)C(N)=O YEDNBEGNKOANMB-REOHCLBHSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- -1 aromatic amino acid Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960002591 hydroxyproline Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN8614A AUPN861496A0 (en) | 1996-03-13 | 1996-03-13 | Lytic peptides |
| PCT/AU1997/000160 WO1997033908A1 (fr) | 1996-03-13 | 1997-03-13 | Peptides lytiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ331771A true NZ331771A (en) | 2000-04-28 |
Family
ID=3792926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ331771A NZ331771A (en) | 1996-03-13 | 1997-03-13 | Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also included |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0901502A4 (fr) |
| AU (1) | AUPN861496A0 (fr) |
| CA (1) | CA2248782A1 (fr) |
| NZ (1) | NZ331771A (fr) |
| WO (1) | WO1997033908A1 (fr) |
| ZA (1) | ZA972186B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9705519D0 (en) * | 1997-03-18 | 1997-05-07 | Anmat Technology Limited | Activation of peptides |
| CA2333855A1 (fr) * | 1998-07-09 | 2000-01-20 | University Of Southern California | Peptides amphiphiles isoles derives de la queue cytoplasmique de proteines de l'enveloppe virale |
| AU6059099A (en) | 1998-09-25 | 2000-04-17 | Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| AU1394500A (en) * | 1998-11-18 | 2000-06-05 | Innature Limited | Product |
| GB9926875D0 (en) * | 1999-11-12 | 2000-01-12 | Microbiological Research Agenc | Use of lytic toxins and toxin conjugates |
| AU2001259837A1 (en) | 2000-05-09 | 2001-11-20 | Greenville Hospital System | Therapeutic pore-forming peptides |
| EP1501935B1 (fr) | 2002-04-22 | 2009-09-23 | Dow Global Technologies Inc. | Production de peptides a bas prix |
| ES2548767T3 (es) * | 2007-01-16 | 2015-10-20 | The Regents Of The University Of California | Nuevos péptidos antimicrobianos |
| CN101952301A (zh) | 2008-02-14 | 2011-01-19 | 3M创新有限公司 | 用于微生物检测的多肽 |
| EP4035685A1 (fr) | 2012-10-30 | 2022-08-03 | Esperance Pharmaceuticals, Inc. | Conjugués anticorps-médicament et procédés d'utilisation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5645996A (en) * | 1994-08-24 | 1997-07-08 | Torrey Pines Institute For Molecular Studies | Melittin-related polypeptides, mixture sets and libraries thereof |
-
1996
- 1996-03-13 AU AUPN8614A patent/AUPN861496A0/en not_active Abandoned
-
1997
- 1997-03-13 CA CA002248782A patent/CA2248782A1/fr not_active Abandoned
- 1997-03-13 WO PCT/AU1997/000160 patent/WO1997033908A1/fr not_active Application Discontinuation
- 1997-03-13 NZ NZ331771A patent/NZ331771A/xx unknown
- 1997-03-13 ZA ZA9702186A patent/ZA972186B/xx unknown
- 1997-03-13 EP EP97906936A patent/EP0901502A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AUPN861496A0 (en) | 1996-04-04 |
| WO1997033908A1 (fr) | 1997-09-18 |
| EP0901502A1 (fr) | 1999-03-17 |
| CA2248782A1 (fr) | 1997-09-18 |
| ZA972186B (en) | 1997-11-10 |
| EP0901502A4 (fr) | 2001-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69835279D1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| NZ333609A (en) | Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells | |
| ATE278708T1 (de) | Conotoxin peptid pviia | |
| NZ331771A (en) | Lytic peptides with amphipathic alpha helices and positively charged N- or C-terminal, methods of activation/inactivation, compositions and methods of treatment are also included | |
| ATE196475T1 (de) | Auf histatin basierende, gegen pilze und bakterien gerichtete peptide | |
| ATE350396T1 (de) | Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung | |
| EP1319023B8 (fr) | Peptide de hsp70 stimulant l'activite de cellules tueuses naturelles (nk) et ses utilisations | |
| PT1290013E (pt) | Derivados dos peptidos apo-ai/aii | |
| WO1997031019B1 (fr) | Peptides antipathogenes et compositions les contenant | |
| DE69736487D1 (de) | Peptidzusammensetzung mit wachstumsfaktor-ähnlicher aktivität | |
| CA2320429A1 (fr) | Peptides antimicrobiens et metapeptides derives | |
| ATE205855T1 (de) | Gegen bakterien, mycota und viren wirksame vertebraten proteine und dessen kosmetische zubereitungen | |
| AR002742A1 (es) | Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn | |
| MY113407A (en) | Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| AU671989B2 (en) | Treatment of tropical spastic paresis with peptide T | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| FR2446292B1 (fr) | ||
| US20020111305A1 (en) | Antiviral peptides | |
| NZ335136A (en) | Isolated peptides which complex with hla-cw*16 molecules, and uses thereof | |
| SE9700301D0 (sv) | New compound | |
| FI20012082A0 (fi) | Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi | |
| SE9302414D0 (sv) | Peptid med oxytocinantagonist-aktivitet | |
| MX2025007570A (es) | Peptido y su uso |